← Back to the boardNews
STAT+: GLP-1s are given an FDA warning for rare eye condition risk
Why it’s here: The FDA safety warning on GLP-1 drugs is a federal regulatory action in biotech/drug regulation, which is in scope, but the item is a newsletter bundling several unrelated stories (Beam CRISPR, PepGen), so it falls under the roundup rejection category.
Trace across the boardItem
5d agoSTATSTAT+: GLP-1s are given an FDA warning for rare eye condition riskFDA ordered GLP-1 drug makers to add safety labeling warning patients and doctors of a potential risk of the rare eye condition NAION. 9 linked
Coverage
1 outlets · first seen 6d agoConnected
3 links- NewsFDA warns against online weight-loss drugs containing uncertain ingredientsBoth involve Food and Drug Administration
- NewsUS FDA orders new eye risk warnings for Ozempic, ZepboundBoth involve Food and Drug Administration
- NewsSTAT+: FDA warns GLP-1 drugs carry potential risk of rare eye conditionBoth involve Food and Drug Administration
About
- Food and Drug Administration